---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000002"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:47:48.067617+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Ligand's ZELSUVMI for molluscum contagiosum in adults and children 1+

## Summary
- FDA approved ZELSUVMI (berdazimer topical gel, 10.3%) for molluscum contagiosum in patients 1 year and older.
- First novel drug for molluscum and first topical prescription that can be applied at home.
- Approximately 6 million Americans infected annually; up to 73% of children go untreated.
- Product expected to be available in the U.S. in the second half of 2024.

## SEC filing metadata
- accession: 0000886163-24-000002
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/0000886163-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000002/lgnd-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000002
- JSON: https://secwatch.observer/filing/0000886163-24-000002.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.